OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Ocugen, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$0.79+0.01 (+0.90%)

Close on Oct 19, 2026

Market cap: $266.64M
P/E (TTM): –
Dividend yield: –

Ocugen, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Depreciation & Amortization	–	–	–	0.48	0.23	–	–	–	–	–	–	–
Stock-Based Compensation	7.71	7.43	9.22	11	6.96	0.66	0.88	1.07	1.57	1.55	1.23	0.55
Other Non-Cash Items	-1.04	-0.04	-0.05	0.67	-0.03	0.35	-0.01	–	–	–	–	–
Change in Accounts Payable	3.31	4.14	-12	9.49	3.50	-0.54	-1.63	3.63	-0.85	-0.44	-2.84	2.03
Operating Cash Flow	-57	-42	-62	-60	-48	-15	-17	-12	-23	-26	-30	-18
Capital Expenditures	-0.19	-3.39	-10	-4.46	-0.94	-0.31	-0.03	-0.08	-0.28	-0.32	-1.95	-3.32
Purchase of Investments	–	0	-3.95	-13	0	0	-2.33	0	-8.00	–	–	–
Sale & Maturity of Investments	–	0	18	0	–	–	–	0.90	7.05	–	–	–
Investing Cash Flow	-0.31	-3.39	3.08	-17	-1.82	-0.31	-2.36	-0.08	-1.23	-0.32	-1.95	-3.32
Share Repurchases	–	–	–	–	0	0	-0.05	0	–	–	–	–
Stock Issued	20	39	21	60	129	38	1.18	0	–	–	4.74	–
Debt Issued	0	30	0.50	0.50	0	–	–	–	–	–	–	1.75
Debt Repaid	–	–	–	–	0	-5.63	-5.29	0	-0.58	-0.58	-0.41	–
Financing Cash Flow	17	65	21	59	121	32	25	7.18	-0.58	27	4.37	71
Foreign Exchange Rate Adjustments	0.01	0.03	-0.01	0.03	0	–	0	0.00	–	–	–	–
Net Change in Cash	-40	19	-38	-18	71	17	5.82	-4.52	-25	0.99	-28	50
Free Cash Flow	-57	-46	-73	-65	-49	-15	-17	-12	-23	-26	-32	-21
Income Taxes Paid	–	–	–	–	–	–	–	0.11	0.20	0.26	0.08	0.00
Interest Paid	–	–	–	–	–	–	–	0.00	0.03	0.07	0.09	0.02

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -1561.4%
Net margin: -1853.9%
Return on equity, FY2025: -776.9%

Financial strength

Current ratio: 0.80
Debt to equity: -0.11
Debt to assets: 1.4%
Cash to current liabilities: 75.2%

Valuation

P/E ratio: –
Price to sales: 60.42
Price to book: –
Dividend yield: –